MannKind (MNKD) recently drew investor attention after reporting positive topline Phase 1b INFLO-1 data for its inhaled nintedanib therapy in idiopathic pulmonary fibrosis patients, highlighting safety, tolerability, and effective deep lung delivery.

The INFLO-1 update has come alongside a sharp move in MannKind’s stock, with a 1-day share price return of 5.66% and a 90-day share price return of 25.30%. However, the year-to-date share price return is down 26.61% and the 3-year total shareholder return is down 22.01%. Taken together, these figures suggest that short term momentum has picked up, while longer term performance has been more mixed.

If MannKind’s recent clinical progress has caught your eye, this can be a good moment to broaden your watchlist and check out 43 healthcare AI stocks.

The recent jump in MannKind’s stock follows upbeat INFLO-1 data, yet the share price is still down over 2026 and over three years. Is this move catching up with fundamentals, or is it mostly a burst of fresh enthusiasm?

Most Popular Narrative: 45.9% Undervalued

The most widely followed MannKind narrative sees fair value well above the last close at $4.11, and ties that gap closely to Afrezza and the inhaled pipeline.

Afrezza's continued double-digit prescription growth, international expansion efforts, upcoming pediatric indication launch, and a broadened salesforce footprint are set to accelerate market penetration amid a rising global diabetes burden and an aging population, directly supporting revenue and earnings growth.

Read the complete narrative. Read the complete narrative.

Curious what justifies a higher fair value for MannKind? The narrative leans heavily on faster earnings growth, rising margins and a richer profit multiple on future results.

Result: Fair Value of $7.59 (UNDERVALUED)

However, MannKind still faces meaningful execution risk related to broader Afrezza adoption and its concentrated exposure to a small group of key products.

Next Steps

With MannKind presenting both clear risks and potential rewards, this is a good time to review the data for yourself and decide where you stand. To see the full balance of concerns and opportunities, check out the 3 key rewards and 1 important warning sign.

Looking for more MannKind investment ideas to compare?

Do not stop with MannKind alone. Use the Simply Wall Street Screener to uncover other stocks that fit your style before the next opportunity passes you by.

• Target potential breakouts by reviewing 20 elite penny stocks with strong financials with stronger balance sheets and financial profiles than many investors might expect.
• Zero in on value focused opportunities by scanning the 52 high quality undervalued stocks that combine quality fundamentals with pricing that may look appealing.
• Prioritise resilience by checking the 83 resilient stocks with low risk scores that score well on financial strength and business risk indicators.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.